期刊文献+

新结构嘧啶类化合物的合成及抗肿瘤活性筛选 被引量:2

Synthesis and antitumor activities of pyrimidines
下载PDF
导出
摘要 目的合成具有抗肿瘤活性的新型CDKs抑制剂,并评价其抗肿瘤活性。方法根据生物活性叠加原理,将1(-甲磺酰基)哌啶-4-氨和嘧啶杂环片段合理组合,设计合成了5个结构新颖的N4-取代苯胺基-N2-(1-甲磺酰基哌啶-4-氨基)-5-硝基嘧啶类化合物3a^3e。结果目标化合物的结构经质谱和核磁共振氢谱等表征确认。采用MTT法测试了目标化合物抑制肿瘤细胞增殖活性。测试结果表明,部分化合物对MCF-7(人乳腺癌细胞)肿瘤细胞有弱的细胞毒性,而对HepG2(人肝癌细胞)没有抑制活性,表现出一定的选择性。结论化合物3b对MCF-7(人乳腺癌细胞)肿瘤细胞有较强的抑制活性(IC50=13.6μmo·lL-1)。初步的构效关系研究表明化合物的立体结构可能对其抗肿瘤活性影响较大。 Objective To synthesize cyclin-dependent kinase(CDKs) inhibitors and assay their antitumor activities. Methods A series of pyrimidines containing different arylamino and 1-(methylsulfonyl) piperidin moieties were designed by combining the segments 1-(methylsulfonyl) piperidin and pyrimidine heterocycles according to the super-postion principle of the reinforcement of biological activities. Results Their structures were characterized by MS and 1H NMR spectra and all the synthesized compounds were screened for their antimicrobial activity with MTT assay. Conclusion The preliminary bioassay showed that compound 3b displayed good antitumor activity(IC50=13.6 μmol/L) . The preliminary structure activity relationship analysis of these analogues suggest that the steric factor may have important impact on the anti-tumor activity.
出处 《南方医科大学学报》 CAS CSCD 北大核心 2011年第5期875-877,共3页 Journal of Southern Medical University
基金 教育部博士点新教师基金(20104433120011) 广东省自然科学基金(10451051501004725) 广东省医学科研基金(B2010185)
关键词 嘧啶 合成 抗肿瘤活性 pyrimidines synthesis antitumor activities
  • 相关文献

参考文献12

二级参考文献35

  • 1Sharma PS, Tyagi R. Inhibitors of cyclin dependent kinases: useful targets for cancer treatment [J] . Curr Cancer Drug Targets, 2008, 8 (1):53-75. 被引量:1
  • 2Campbell Mclnnes Progress in the evaluation of CDK inhibitors as anti-tumor agents[J].Drug Discovery Today, 2008, 13( 19):875-881. 被引量:1
  • 3Coley, H.M., Shotton, C.F. Selicielib ( CYC202 ; R-Roseovitine ) in Combination with Cytotoxie Agents in Human Uterine Sarcoma Cell Lines[J].Anticancer Res., 2007, 27(1A) : 273-278. 被引量:1
  • 4Jozefa, Wesierska-Gadek. Dual action of the inhibitors of cyclin-dependent kinases: targeting of the cell-cycle progression and activation of wild-type p53 protein [J]. Expert Opin Investig Drugs, 2006,15 ( 1 ) : 23-38. 被引量:1
  • 5Emmanuel Agbottahl, Wen-I Yehl, Reem Berrol, et al. Two specific drugs, BM8-345541 and purvalanol A induce apoptosis of HTLV-1 infected cells through inhibition of the NF-kappaB and cell cycle pathways[J]. AIDS Research and Therapy 2008, 5:12. 被引量:1
  • 6Vandromme. L, Piguel. S, Lozach. O, Meijer L.. Legraverend, M. Griersons, D.S.Suzuki Type Pd (0) Coupling Reactions in the Synthesis of 2- Arylpurines as CDK Inhitors[J].Bioorg Med Chem Lett, 2006, 16(12) : 3144-3146. 被引量:1
  • 7De Pinto. W, Chu. X. J, Yin X. In vitro and in vivo Activity of R547: a Potent and Selective Cyclin-Dependent Kinaze Inhibitor Currently in Phase I Clinical Trials[J].. Mol Cancer Ther, 2006, 5 ( 11 ) : 2644- 2658. 被引量:1
  • 8Huang.S, Li, R, Connolly, P.J., Emanuel, S., Middleton, S. A. Synthesis of 2-Amino-4- ( 7-azaindob 3-yl) pyrimidines as Cyelin Dependent Kinase 1 ( CDK1 ) Inhibitors [J]. Bioorg. Med Chem Lett. 2006, 16(18) :4818-4821. 被引量:1
  • 9Clifford D.Jones, David M. Andrews, Andrew J. Barker, et al. Imidazole pyrimidine amides as potent, orally bioavailable cyclin-dependent kinase inhibitors[J]. Bioorganic & Medicinal Chemistry Letters 18, 2008 : 6486-6489. 被引量:1
  • 10Xiaojuan, Yanga. c, Xiaobin, et al. A novel liposomal formulation of flavopirldoi [J].International Journal of Pharmaceutics 365(2009) : 170-174. 被引量:1

共引文献22

同被引文献14

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部